Stock listing
NASDAQ:PMN ProMIS Neurosciences Inc. Stock
Home listing (NASDAQ) of ProMIS Neurosciences Inc.
Follow ProMIS Neurosciences Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PMN
$3.98 USD -0.07 (-1.7%)
Close on Nov 10, 2026
- Day range
- $3.88 – $4.30 USDNov 10, 2026
- Volume
- 212,690 sharesNov 10, 2026
- Market cap
- $35.69M USDAt the close on Nov 10, 2026 · price × 8.97M shares outstanding
- 52-week range
- $2.78 – $27.40 USDLowest and highest trades, Nov 11, 2025 – Nov 10, 2026
- Traded on an average day
- $762,327 USDMedian day 30,050 shares · last 3 months, Aug 10, 2026 – Nov 10, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PMN · Home | $3.98 USD | -0.07 (-1.7%) | 212,690 | $3.99 | $4.30 | $3.88 | $4.05 | Close on Nov 10, 2026 |
| Frankfurt:23J | €3.12 EUR | -0.06 (-1.9%) | — | €3.12 | €3.12 | €3.12 | €3.18 | Close on Nov 10, 2026 |
Daily closes
Last 3 months, Aug 10, 2026 – Nov 10, 2026 · NASDAQ:PMN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.98 | -0.07 | -1.7% | $3.99 | $4.30 | $3.88 | 212,690 | |
| $4.05 | -0.11 | -2.6% | $4.24 | $4.30 | $4.00 | 156,812 | |
| $4.16 | +0.51 | +14.0% | $3.76 | $4.33 | $3.70 | 375,100 | |
| $3.65 | +0.13 | +3.7% | $3.55 | $3.76 | $3.40 | 270,300 | |
| $3.52 | +0.11 | +3.2% | $3.41 | $3.54 | $3.02 | 515,400 | |
| $3.41 | +0.41 | +13.7% | $3.29 | $3.62 | $3.28 | 993,700 | |
| $3.00 | -0.31 | -9.4% | $3.59 | $4.50 | $2.78 | 3,536,000 | |
| $3.31 | -7.77 | -70.1% | $8.41 | $8.53 | $3.21 | 1,639,800 | |
| $11.08 | +0.01 | +0.1% | $10.87 | $11.38 | $10.35 | 132,800 | |
| $11.07 | +1.39 | +14.4% | $9.58 | $11.76 | $9.58 | 50,600 | |
| $9.68 | +1.62 | +20.1% | $8.36 | $10.28 | $8.36 | 53,100 | |
| $8.06 | -0.28 | -3.4% | $8.46 | $8.87 | $7.74 | 22,000 | |
| $8.34 | -0.64 | -7.1% | $8.65 | $8.80 | $8.24 | 10,400 | |
| $8.98 | -0.15 | -1.6% | $9.06 | $9.31 | $8.88 | 6,400 | |
| $9.13 | +1.04 | +12.9% | $8.40 | $9.13 | $8.18 | 7,500 | |
| $8.09 | -0.14 | -1.7% | $8.34 | $8.65 | $8.06 | 30,300 | |
| $8.23 | +0.08 | +1.0% | $8.36 | $8.39 | $8.06 | 11,300 | |
| $8.15 | -0.55 | -6.3% | $8.89 | $9.64 | $7.94 | 20,400 | |
| $8.70 | +0.41 | +4.9% | $8.29 | $8.87 | $8.00 | 33,500 | |
| $8.29 | -0.37 | -4.3% | $8.41 | $8.81 | $8.16 | 23,400 | |
| $8.66 | -0.79 | -8.4% | $9.38 | $9.47 | $8.51 | 27,100 | |
| $9.45 | -0.16 | -1.7% | $9.61 | $9.78 | $9.20 | 23,700 | |
| $9.61 | +0.46 | +5.0% | $9.06 | $10.15 | $9.06 | 18,800 | |
| $9.15 | +0.03 | +0.3% | $9.02 | $9.37 | $8.78 | 35,300 | |
| $9.12 | -0.09 | -1.0% | $9.17 | $9.52 | $9.01 | 25,100 | |
| $9.21 | -0.16 | -1.7% | $9.46 | $9.52 | $8.78 | 26,400 | |
| $9.37 | -0.03 | -0.3% | $9.50 | $9.77 | $9.07 | 38,200 | |
| $9.40 | +0.02 | +0.2% | $9.44 | $10.38 | $9.16 | 27,300 | |
| $9.38 | -1.47 | -13.5% | $10.98 | $10.98 | $9.21 | 102,100 | |
| $10.85 | +0.21 | +2.0% | $10.68 | $11.32 | $10.42 | 12,700 | |
| $10.64 | -0.01 | -0.1% | $10.56 | $11.10 | $10.53 | 16,900 | |
| $10.65 | -0.62 | -5.5% | $11.15 | $11.57 | $10.51 | 25,100 | |
| $11.27 | -0.30 | -2.6% | $12.06 | $12.06 | $11.15 | 20,100 | |
| $11.57 | -1.37 | -10.6% | $12.83 | $13.06 | $11.29 | 52,700 | |
| $12.94 | -0.64 | -4.7% | $13.45 | $13.78 | $12.94 | 43,700 | |
| $13.58 | -0.05 | -0.4% | $13.80 | $14.22 | $13.45 | 94,200 | |
| $13.63 | -0.38 | -2.7% | $13.54 | $14.22 | $13.13 | 26,200 | |
| $14.01 | +0.55 | +4.1% | $13.52 | $14.21 | $13.52 | 24,000 | |
| $13.46 | +0.58 | +4.5% | $13.00 | $13.70 | $12.88 | 22,800 | |
| $12.88 | -0.01 | -0.1% | $13.25 | $13.25 | $12.40 | 33,300 | |
| $12.89 | -0.37 | -2.8% | $13.55 | $13.93 | $12.70 | 49,100 | |
| $13.26 | -0.30 | -2.2% | $13.05 | $13.56 | $13.05 | 21,800 | |
| $13.56 | +0.16 | +1.2% | $13.48 | $13.94 | $13.01 | 20,000 | |
| $13.40 | -0.97 | -6.8% | $14.28 | $14.28 | $12.98 | 54,100 | |
| $14.37 | +1.84 | +14.7% | $12.88 | $14.96 | $12.26 | 126,800 | |
| $12.53 | -0.07 | -0.6% | $12.51 | $13.13 | $12.27 | 38,000 | |
| $12.60 | -0.30 | -2.3% | $13.03 | $13.46 | $12.48 | 24,000 | |
| $12.90 | -1.08 | -7.7% | $13.90 | $14.16 | $12.76 | 37,400 | |
| $13.98 | +0.63 | +4.7% | $13.45 | $14.28 | $13.22 | 89,600 | |
| $13.35 | +0.28 | +2.1% | $13.25 | $14.31 | $13.01 | 42,300 | |
| $13.07 | -0.72 | -5.2% | $13.79 | $14.34 | $13.07 | 24,600 | |
| $13.79 | -0.20 | -1.4% | $14.07 | $14.60 | $13.47 | 51,500 | |
| $13.99 | -0.47 | -3.3% | $14.62 | $15.19 | $13.92 | 17,400 | |
| $14.46 | -0.90 | -5.9% | $15.21 | $15.21 | $14.16 | 32,200 | |
| $15.36 | +0.56 | +3.8% | $15.00 | $15.36 | $14.50 | 60,600 | |
| $14.80 | +0.29 | +2.0% | $14.44 | $15.46 | $14.23 | 38,600 | |
| $14.51 | -0.40 | -2.7% | $15.05 | $15.05 | $14.41 | 7,200 | |
| $14.91 | +0.25 | +1.7% | $14.96 | $14.96 | $14.44 | 16,200 | |
| $14.66 | -0.32 | -2.1% | $15.36 | $15.50 | $14.40 | 22,500 | |
| $14.98 | +0.32 | +2.2% | $14.66 | $15.00 | $14.07 | 17,100 | |
| $14.66 | -0.20 | -1.3% | $14.69 | $14.96 | $14.27 | 25,100 | |
| $14.86 | +0.07 | +0.5% | $15.28 | $15.28 | $14.45 | 29,800 | |
| $14.79 | +0.29 | +2.0% | $14.62 | $15.00 | $14.32 | 14,700 | |
| $14.50 | -0.47 | -3.1% | $15.00 | $15.00 | $14.10 | 12,800 | |
| $14.97 | +0.25 | +1.7% | $14.60 | $15.00 | $13.96 | 32,600 | |
| $14.72 | +0.01 | +0.1% | $14.96 | $16.01 | $14.00 | 49,200 |
Splits
2 splits since 2022 · NASDAQ:PMN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-60 | Consolidation |
- Ticker
- NASDAQ:PMN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in November
Latest earnings call · Aug 13, 2026
ProMIS Neurosciences (NASDAQ:PMN) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Jul 28, 2026
Technical Presentation (July 2026)
Technical · 27 slides
Calls
Replays
ProMIS Neurosciences (NASDAQ:PMN) Q2 2026 Earnings Call
Thu, Aug 13, 2026 · 4:30 PM ET
Watch Transcript
Latest news
ProMIS Neurosciences to Participate in Upcoming Conferences in November
Nov 5, 2026
Closed $3.65 (+3.7%) on Nov 5, 2026
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
Nov 3, 2026
Closed $3.41 (+13.7%) on Nov 3, 2026
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Oct 6, 2026
Closed $9.21 (-1.7%) on Oct 6, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Sep 1, 2026
Closed $13.35 (+2.1%) on Sep 1, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Aug 13, 2026
Closed $14.86 (+0.5%) on Aug 14, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Aug 3, 2026
Closed $13.57 (-4.0%) on Aug 4, 2026
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
Jul 28, 2026
Closed $14.52 (+23.9%) on Jul 28, 2026
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
Jul 27, 2026
Closed $14.52 (+23.9%) on Jul 28, 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
Jul 14, 2026
Closed $13.66 (+6.7%) on Jul 14, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in June
May 28, 2026
Closed $10.87 (+3.7%) on May 28, 2026
Financings
Private placement of common shares, common share warrants and pre-funded warrants
Jan 30, 2026
Announced: US$75M–US$175M · US$10.77 a share · Warrants at US$14.4 · Guggenheim Securities +2
Dealers: Guggenheim Securities (lead), Ceros Financial Services, Inc., Leede Financial Inc.
Buyers: Janus Henderson (co-leading the PIPE financing); Ally Bridge Group (co-leading the PIPE financing); Deep Track Capital; Great Point Partners, LLC; Trails Edge Capital Partners; Wellington Management; Woodline Partners LP
Insiders: 725,221 Common Shares sold at $12.13 per share to certain affiliates and insiders of the Company
Use of proceeds: Complete the Phase 1b Alzheimer's disease study and accelerate development of the subcutaneous formulation of PMN310
Private placement of warrants
Jul 28, 2025
Announced: about US$3M · US$0.1875 a share · Warrants at US$1.25 for 60 months
Buyers: Ally Bridge Group
Use of proceeds: Advance clinical development of PMN310, working capital and general corporate expenses
Warrant exercise of existing warrants
Jul 28, 2025
Announced: US$9M
Registered direct offering of pre-funded warrants
Jul 22, 2025
Announced: about US$800,000 · US$0.8124 a share
Buyers: existing healthcare focused institutional investor ($0.8 million)
Use of proceeds: Clinical development of PMN310, its lead therapeutic candidate, plus working capital and general corporate expenses
Decks
Technical Presentation (July 2026)
Technical · 27 slides · Jul 28, 2026
Technical Presentation (July 2026)
Technical · 27 slides · Jul 22, 2026
Investor Presentation (2026)
Investor deck · 16 slides · 2026
Investor Presentation (January 2025)
Investor deck · 34 slides · Jan 27, 2025
ProMIS Neurosciences Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 82 in all · newest Nov 5, 2026 · oldest 2022
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 13, 2026
- Decks
- 5 decks · latest Jul 28, 2026
Where ProMIS Neurosciences Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PMN · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A41MFQ | LS Exchange | Germany | EUR |
| Lang & Schwarz:A41MFQ | Lang & Schwarz | Germany | EUR |
| BOATS:PMN | BOATS | United States | USD |
| Dusseldorf:23J | Dusseldorf | Germany | EUR |
| Frankfurt:23J | Frankfurt | Germany | EUR |
| Stuttgart:23J | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about ProMIS Neurosciences Inc.